Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Genetic Association With Various Severities, Phenotypes and Endotypes of Asthma.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

There is limited information on genetics associated with asthma in Chinese. An earlier meta-analysis found that ADAM33, FcεRIb, RANTES, TNF-a, ACE, b2-AR, IL-4R and IL-13 genes could be proposed as asthma susceptible genes in the Chinese population. However, given the limited number of studies, more data are required to validate these associations. Future research must address key issues such as the broad clinical variability of asthma and the underrepresentation of populations of non-European heritage. Endotype-specific SNPs and unique biological insights may be obtained by conducting GWAS/EWAS on homogeneous populations of more therapy-resistant T2-low, adult-onset, obesity-associated asthma or asthma with particular co-morbidities. The primary objective is to investigate the association between genetic polymorphisms and various severities of asthma.

Who May Be Eligible (Plain English)

Who May Qualify: - • All patients with confirmed diagnosis of asthma (defined as those with a consistent history and prior documented evidence of variable airflow obstruction, with evidence of an increase in FEV1 greater than 12% or 400 mL following bronchodilator or bronchial hyperresponsiveness on bronchial provocation testing, when stable) 12 - Able to sign written willing to sign a consent form form to participate in the study. Who Should NOT Join This Trial: - • Patients currently with acute exacerbation of asthma by GINA guideline. (For subjects with asthma exacerbation, they can join the study after 6 weeks post recovery from the exacerbation.) - Patients with respiratory diseases that can show similar symptoms to chronic airway diseases such as bronchiectasis, tuberculosis(TB)-destroyed lung parenchyma, endobronchial TB, and lung cancer, or those who have history of these diseases based on physician's judgment. - Patients currently diagnosed with pneumonia and acute bronchitis. For control subject: the inclusion will be having no clinical diagnosis of asthma. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * • All patients with confirmed diagnosis of asthma (defined as those with a consistent history and prior documented evidence of variable airflow obstruction, with evidence of an increase in FEV1 greater than 12% or 400 mL following bronchodilator or bronchial hyperresponsiveness on bronchial provocation testing, when stable) 12 * Able to sign written informed consent form to participate in the study. Exclusion Criteria: * • Patients currently with acute exacerbation of asthma by GINA guideline. (For subjects with asthma exacerbation, they can join the study after 6 weeks post recovery from the exacerbation.) * Patients with respiratory diseases that can show similar symptoms to chronic airway diseases such as bronchiectasis, tuberculosis(TB)-destroyed lung parenchyma, endobronchial TB, and lung cancer, or those who have history of these diseases based on physician's judgment. * Patients currently diagnosed with pneumonia and acute bronchitis. For control subject: the inclusion will be having no clinical diagnosis of asthma.

Treatments Being Tested

GENETIC

No intervention

No intervention

Locations (2)

The Chinese University of Hong Kong
Hong Kong, New Territories, Hong Kong
The Chinese University of Hong Kong
Hong Kong, Hong Kong